Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Kelderman, Sander
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. [electronic resource] - Cancer immunology, immunotherapy : CII May 2014 - 449-58 p. digital
Publication Type: Clinical Trial; Journal Article
1432-0851
10.1007/s00262-014-1528-9 doi
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal--therapeutic use
Biomarkers, Tumor--analysis
Disease-Free Survival
Female
Humans
Ipilimumab
Kaplan-Meier Estimate
L-Lactate Dehydrogenase--blood
Male
Melanoma--drug therapy
Middle Aged
Skin Neoplasms--drug therapy
Treatment Outcome
Young Adult
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. [electronic resource] - Cancer immunology, immunotherapy : CII May 2014 - 449-58 p. digital
Publication Type: Clinical Trial; Journal Article
1432-0851
10.1007/s00262-014-1528-9 doi
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal--therapeutic use
Biomarkers, Tumor--analysis
Disease-Free Survival
Female
Humans
Ipilimumab
Kaplan-Meier Estimate
L-Lactate Dehydrogenase--blood
Male
Melanoma--drug therapy
Middle Aged
Skin Neoplasms--drug therapy
Treatment Outcome
Young Adult